Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥30.00 - ¥103.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥3.21B
Enterprise Value¥559.46M
Total Cash (Recent Filing)¥3.26B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.01
Shares Outstanding97,334,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Low Reported DebtBalance-sheet leverage is conservative with no reported debt in 2024–2025. This durable advantage reduces mandatory interest costs and refinancing pressure, giving management more optionality to pursue partnerships or staged R&D funding before taking on leverage.
Focused R&D NicheA clear strategic focus on gene expression–modulating therapeutics for genetic diseases creates a durable scientific specialization. That focus can build platform expertise, raise entry barriers, and improve efficiency in candidate selection and partnering, supporting long-term value if clinical progress continues.
Lean Operating StructureA very small employee base implies a lean operating model with lower fixed payroll obligations. Over the medium term this can extend cash runway, concentrate R&D spending on core programs, and allow quicker decision cycles—important for a pre-revenue biotech managing scarce capital.
Bears Say
Persistent Cash BurnOperating and free cash flows are consistently and materially negative, with burn accelerating in 2025. This structural cash outflow creates ongoing financing needs, increases dilution or partnership dependence, and heightens execution risk if capital markets tighten or partner deals slow.
Minimal-to-zero RevenueThe company has generated minimal-to-zero revenue in recent years and therefore lacks commercial cash generation. Absent product commercialization or licensing income, the business remains dependent on external funding, exposing it to execution and clinical risk before any durable revenue stream emerges.
Shrinking Equity BaseCumulative losses have materially eroded shareholders' equity over several years. A thinner equity cushion reduces balance-sheet resilience, narrows financing options, and increases the probability of dilutive capital raises or constrained investment in programs if losses persist.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥30.00 and its highest was ¥103.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥3.21B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 40 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on May 14, 2026. The company reported -¥3.64 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.64.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 97,334,100 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥3.64 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―